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Abstract
Background: Treatment with oral anticoagulant may influence the quality of life perception as it promotes
changes in the patient’s life, not offering an evident symptomatic relief and presenting well defined risks, such as
bleeding. In this trial, the influence of chronic use of anticoagulants on the quality of life perception has been
analyzed in patients assisted at the anticoagulation outpatient unit.
Methods: The health related quality of life was evaluated through a cross-section study with a sample composed
of 72 patients seen from July 23, 2009 to September 2, 2010 at the Anticoagulation Outpatient Unit of the Federal
University of Bahia’s University Hospital. The study’s population was composed by patients with atrial fibrillation
and mechanical heart valve. The patients were submitted to two quality of life evaluation questionnaires: a generic
questionnaire - the Medical Outcomes Study SF-36 Health Survey (SF36) - and a specific questionnaire - the Duke
Anticoagulation Satisfaction Scale (DASS).
Results: The quality of life perception of the patients studied, based on both the DASS and the SF36, was positive
regarding the treatment with oral anticoagulant. The SF36 presented an average score of 62.2 (± 20.0). Among the
SF36 evaluated domains, the physical-emotional aspect was the most compromised one regarding life quality
perception. The DASS presented an average score of 67.1 (± 18.2) and the domain presenting a greater
compromise was the one related to the treatment inconveniences (annoyances, burdens and obligations). Previous
hemorrhagic event, comorbidities, drug interactions with medicines that increase the anticoagulant effect, lower
education level in the SF36 and younger age group influence a more negative perception of the quality of life,
whereas lower education level in the DASS and the duration of treatment for more than 1 year offer a more
positive perception.
Conclusion: Patients seen at the anticoagulation outpatient unit of the University Hospital of Federal University of
Bahia/Brazil had a positive perception of the treatment. Factors such as hemorrhagic event, comorbidities, drug
interactions, education level, age group and duration of treatment have an influence on the quality of life
perception.
Background
The quality of life (QoL), according to World Health
Organization - WHO (1947), is a wide concept involving
several factors affecting the life of a person, such as
social condition, health, economical status, satisfaction
and welfare. The QoL aims at getting to know the diffi-
culties of living with a disease, and such difficulties may
be subjective and diverse for each patient [1]. Therefore,
the QoL is related to the perception the subject has of
his/her health status and of the disease effects on his/
her life, involving both physical and functional aspects
besides emotional and social ones.
Long-term oral anticoagulation is a required treatment
for specific patients with atrial fibrillation (AF) and
mechanical heart valve (MHV) and for the prophylaxis
of strokes and other thromboembolic events. However,
a therapy with coumarinic agents (warfarin and phen-
procoumon) is complicated due to the variability of the
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any medium, provided the original work is properly cited.biological effect, its narrow therapeutic index and poten-
tial occurrence of thrombotic or bleeding events.
The oral anticoagulant therapy control is complex and
requires frequent analytical checking, with several visits
to health units to control the INR (International Nor-
malized Rate). The chronic use of oral anticoagulants
can promote an influence on the patient’sp e r c e p t i o n
regarding his/her QoL and health status due to the
changes it promotes in the patient’sl i f es t y l e ,a n d
mainly because patients are submitted to a treatment
that brings no symptomatic benefit, but presents a well-
defined risk. Thus, it is noted the importance of getting
to know the difficulties involving living with oral antic-
oagulant treatments.
Few previous studies have evaluated QoL in patients
presenting cardiopathy and chronic use of oral anticoa-
gulant drugs. Casais[2], in a study conducted in Buenos
Aires, Argentina, has shown a positive perception of to
the use of oral anticoagulant drugs among patients pre-
senting all the indications. Patients with cardiopathies
were the majority of the studied population.
The objective of the study was to analyze the QoL of
patients with chronic use of oral anticoagulants in a uni-
v e r s i t yh o s p i t a li nt h es t a t eo fB a h i at h r o u g ht h e
obtained scores via the application of the QoL SF36 and
DASS instruments, besides evaluating the influence of
clinical and demographic factors in the perception of
quality of life. This regional evaluation is important,
considering that cultural and subjective aspects play an
important role in the negative or positive perception of
patients submitted to anticoagulation treatment.
Method
QoL was evaluated through a cross-section study with a
sample composed of 72 patients seen from July 23, 2009
to September 2, 2010 at the Anticoagulation Outpatient
Unit of the University Hospital of Federal University of
Bahia.
The sample was composed of patients with AF and
MHV, regardless gender or race, living in Salvador - the
capital city - and in the countryside part of Bahia, under
chronic treatment with oral anticoagulants. The inclu-
sion criteria were: patients with AF and/or MHV, under
chronic treatment with oral anticoagulant, who agreed
to sign an informed consent form. The exclusion criteria
were: anticoagulated patients by means other than AF or
MHV and who were not capable of answering all the
questions in the QoL questionnaire applied.
The sampling type was chosen according to its conve-
nience. The patients were identified through the cardiol-
ogy service the anticoagulation outpatient, and those
who fulfilled the inclusion criteria were invited to take
part in the research. The invitation and questionnaire
application both took place while patients waited
between the execution of the PT and INR exam and the
result for their appraisal.
The anticoagulation outpatient department of Profes-
sor Edgard Santos university hospital complex was cho-
sen as site of this research since it is a public service of
high patient demand for PT and INR exams, and
because it offers specialized assistance to such patients,
with a team composed of a cardiologist doctor and a
pharmacist. The service consists of an evaluation of the
anticoagulation level of the patient (PT and INR) con-
sidering the reason for using the anticoagulant and risk
factors, the evaluation of the interactions of the anticoa-
gulant and others medicaments and/or food, the adjust-
ment of the oral anticoagulant’s dose when necessary,
the orientation of the patient regarding the used dose,
the existing interactions, use time, the importance of
his/her adherence to the treatment and the evaluation
of hemorrhage signals when INR is elevated.
Data collection was conducted through the application
of two questionnaires, one generic and one specific, to
evaluate the subject’s QoL. The QoL generic instrument
w a st h eS F 3 6 ,w h i c hi n v o l v e sa s p e c t ss u c ha sp h y s i c a l
function, performance status, pain, overall health status,
mental health, emotional and social aspects, and vitality.
It is a multidimensional questionnaire and its scores
vary from 0 to 100, with zero regarding the worse and
100 the best QoL for each domain. The specific instru-
ment DASS is an specific scale to evaluate the QoL of
patients under treatment with oral anticoagulants, invol-
ving limitations, displeasure and burden (daily displea-
sure, such as regular return for medical visits and wait
for blood tests results), and positive psychological
impacts. The items presenting the lowest scores show
the higher satisfaction with QoL[3]. The overall score
varies from 25 to 175. The instrument is divided in
three domains: limitation (score from 9 to 63), treat-
ment inconvenience (score from 8 to 56) and psycholo-
gical impact (score from 8 to 56) [4]. There was no
adaptation of the questionnaire for use with the studied
population. An analysis of the subscales was made by
adding the answers to the items (varying from 1 to 7 for
each item) in each domain and reaching the total score
by adding up all the questionnaire items. Clinical, demo-
graphic, and socioeconomic variables were collected by a
questionnaire formulated by the investigator to obtain
such data, which was applied at the same moment of
the generic and the specific questionnaire.
The QoL questionnairs (both generic and specific)
were applied via a paper form by a pharmaceutical pro-
fessional. None of the questions in the QoL question-
naires was omitted or altered.
The descriptive data analysis was made by using the
frequencies for the categorical variables and the contin-
uous quantitative variables were described based on
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analysis were made at Excel 1.0 and SPSS 17.0
softwares.
This study was submitted and approved by the
Research Ethics Committee of Climério de Oliveira
Maternity Hospital (OPINION/ADDITIVE RESOLU-
TION No. 153/2009), and all patients included in the
s t u d ys a m p l eh a v es i g n e dt h ei n f o r m e dc o n s e n tf o r m ,
according to the directives of Resolution 196/96 of the
National Health Council.
Results
Table 1 shows the subjects characteristics. The study’s
population was composed of 72 patients of both
Table 1 Study population characteristics
Age range (years) 22 to 87
Female (%) 62.5
Race (%)
Black 48.6
White 20,8
Mulatto 9,7
Other 20,8
Education (%)
Illiterate 9.7
Incomplete primary education 45.8
Complete primary education 6.9
Incomplete high school 18.1
Complete high school 18.1
Incomplete University course 1.4
Married (%) 52.8
Anticoagulation reason (%)
AF 48.6
MHV 45.8
AF and MHV 5.6
Existence of comorbidities (%) 59.7
Use of drugs in addition to an anticoagulant (%) 98.6
Increase the anticoagulant effect 45.8
Decrease the anticoagulant effect 2.8
Anticoagulant (%)
Warfarin 72.2
Phenprocoumon 27.8
Treatment length (%)
Less than 01 year 16.7
Between 01 to 08 years 52.8
More than 08 years 26.4
Existence of previous bleeding (%)
Yes 37.5
No 62.5
Serious Hemorrhage Percentage and slight bleeding/bruise*
Slight hemorrhage/bruise 92,3
Serious Hemorrhage 7,7
Hospitalization after treatment with anticoagulant due to complications with anticoagulant or for its dose adjustment. (%)**
Yes 20.8
No 79.2
Required emergency care due to anticoagulation (%)**
Yes 38.9
No 61.1
* Considering slight hemorrhages those whose conduct restricts to clinic observation or anticoagulant dose adjustment, and serious hemorrhages those which
require anticoagulant suspension, blood replacement and/or internment.
** These answers are based on patient responses and not validated by review of the medical records
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ber of patients inquired for consent in order to take part
in the research was 73, and all 73 consented although 1
was excluded for not being capable of answering the
questionnaire.
The DASS analysis showed a mean QoL score of 67.1
(± 18.2). The mean score of different domains compos-
ing the instrument is described in Table 2. Among the
domains evaluated, the domain regarding treatment
inconveniences (annoyance, burden, and obligations
with treatment) showed a higher compromise of the
QoL perception in the chronic treatment with an oral
anticoagulant.
The SF36 analysis (Table 3) showed a mean score of
62.2 (± 20.0). The compromising of the different
domains composing this instrument, in ascending order,
were social aspects, overall health status, mental health,
vitality, performance status, pain, emotional and physical
aspects.
Several demographic and clinical aspects described in
T a b l e4m a yp o s i t i v e l yo rn e g a t i v e l yi n f l u e n c et h eQ o L
perception. The QoL perception among the MHV and
FA patients may present a variation either in the SF36
or in the DASS. MHV patients presented a better QoL
perception in comparison to FA patients.
Discussion
Most of the patients studied, based on the DASS and
SF36, showed a positive perception regarding the QoL
when in treatment with oral anticoagulant. Such finding
in regard to the overall QoL is similar to that noted in
the study of Casais [2], in which most patients showed a
positive perception of the oral anticoagulant treatment.
The SF36 and the DASS proved to be adequate instru-
ments to evaluate the patients’ QoL. Both instruments are
easy to use and self-explanatory. The specific DASS instru-
ment offers points in the anticoagulant treatment that may
influence the treatment directly or indirectly, such as fear
of bleeding, changes of behavior, limitations towards treat-
ment, etc. Applying the two questionnaires at the same
time took quite a while, about 30 to 40 minutes for each
patient, as the DASS questionnaire consists of 25 ques-
tions and the SF36 has 11 questions and 36 items.
The QoL perception of the study population showed
a slight variance within the age group. Patients ranging
from 41 to 65 years old showed a better QoL score
when compared to younger patients and patients over
65 years old. Gadisseur [5] evaluated in his study the
effect on the QoL of different modalities of treatment
- self-handling and handling by specialized anticoagu-
lation clinic. In this study [5], it has been observed
that younger patients had better satisfaction with the
anticoagulant treatment than older patients. Therefore,
the variation in the QoL perception between young
patients and older patients is in accordance with such
study.
A higher tendency to the positive perception on QoL
was observed in patients with lower education level in
DASS, for which illiterate patients showed a more posi-
tive perception of QoL, while for SF36 a better percep-
tion of QoL is associated to a higher education level,
except for incomplete college education. According to
Casais [2], the positive perceptions more present in
patients with low education level (illiterates or who only
completed elementary school) may be related to the
association of the anticoagulant treatment to sensations
of health improvement.
According to Casais, the negative perceptions regard-
ing oral anticoagulant treatment was more present in
patients at the beginning of treatment, usually less than
1 year of treatment. This was also observed in this
study, in the two QoL measurement instruments, in
which patients with treatment duration below 1 year
had a higher compromise regarding QoL. Patients
between 1 and 8 years of treatment and patients with
over 8 years of treatment showed, increasingly, a more
positive perception of the treatment.
Regarding the existence of a bleeding event, patients
who had already had previous bleeding, regardless the
bleeding process severity, had a more negative percep-
tion of QoL, in both evaluation instruments. The
domain showing higher compromise was the physical
aspect in SF36 and annoyance and burden with treat-
ment in DASS. Lancaster [6] noticed that patients who
had a bleeding episode showed a significant decrease of
health perception and concludes that, generally, the
Table 2 Mean Score of the domains in the Specific
Questionnaire DASS
Mean Standard deviation
Limitation with treatment 21.8 0.7
Inconvenient with treatment 23.7 2.0
Positive psychological impact 22.6 1.7
Table 3 Mean Score of the domains in the Quality of Life
Scale SF36
Mean Standard deviation
Performance Status 60.1 25.7
Physical appearance 52.4 41.1
Pain 58.8 28.0
Overall health status 65.5 21.6
Vitality 60.3 22.1
Social aspects 80.4 23.8
Emotional aspect 57.9 42.6
Mental health 61.6 18.0
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reduction, unless when a previous bleeding episode
o c c u r s .W h i l eC a s a i s[ 2 ]s h o w e dt h a tt h en e g a t i v ep e r -
ceptions related to anticoagulant treatment was more
evident in patients worried about bleeding risks, but
that bleeding episodes were not associated with negative
QoL perceptions.
Variables such as drug interactions and comorbidities
may also promote changes in QoL perception. Regard-
ing the drug interaction variable, it was observed that
patients using drugs that increase the effect of anticoa-
gulant have higher QoL compromise when compared to
patients who use drugs that reduce the anticoagulant
effect.
The existence of comorbidities promotes a less posi-
tive perception of QoL compared to patients without
comorbidities. This fact may be related to risk factors
that are characterized, most of the time, by the presence
of some comorbidities, as it occurs with FA patients,
who present as risk factors for stroke, age >75 years,
hypertension, thyrotoxicosis, diabetes, cardiovascular
disease, congestive heart failure and stroke history, tran-
sient ischemic attack or thromboembolism [7].
According to Abhay [8], treatment complications with
the oral anticoagulant, such as bleeding, and the incon-
venience of required periodic monitoring, may reduce
patients’ QoL. However, patients may be more exposed
to the potential consequences of not being treated with
an anticoagulant, such as stroke, and less annoyed with
the adverse effects of an oral anticoagulant. An observa-
tion study [9] showed that patients at high stroke risk
valued more the fact of avoiding stroke than avoiding
bleeding.
The QoL of patients with AF and MHV may present
some variance on both research instruments. In the
study, there was a positive trend of the QoL perception
in patients with MHV in comparison to patients using
an anticoagulant due to AF. In his study Casais [2] also
observed a variation of the QoL scores depending on
the indication for treatment with oral anticoagulant and
showed that patients with AF feared more bleeding than
patients with heart prosthesis, despite their having a
lower absolute risk of bleeding [2]. The higher negative
perception of patients with AF may be related to factors
of the disease, in addition to the fact that, for patients
with AF, the choice of anticoagulation is made accord-
ing to the risk/benefit ration, and, therefore, it is limited
to patients at moderate or high risk of stroke [7].
Study Limitations
The current study was conducted within a specialized
service to follow-up patients using oral anticoagulants
that provides individual care, involving the control of
anticoagulation and guidance on the treatment, drug
and food interactions, and promotion of self-care, which
might have lessened the treatment adverse aspects and,
as a consequence, have contributed to a more positive
attitude regarding the QoL. The DASS instrument used
has been validated in Brazil, where the study was carried
out, by Flavia Martinelle Pelegrino, having cultural, con-
ceptual and semantic equivalence, thus not presenting
any additional limitation to the work, besides its results
matching the SF36’s. The questionnaire SF36 was trans-
lated and validated in 1997 by Rozana Mesquita Cico-
nelli presenting cultural equivalence [10].
Conclusion
This study showed that most patients under chronic
treatment with oral anticoagulant showed a positive per-
ception of QoL when attending an anticoagulation spe-
cialized outpatient service. However, this perception was
influenced by demographic and clinical variables, which
had a positive effect on the quality of life (low education
level on DASS, duration of treatment superior to 1 year)
or a negative one (previous hemorrhagic event, comor-
bidities, drug interactions with medicines that increase
the anticoagulant effect, low education level on SF36
and younger age group). Since the QoL instrument was
not applied at two different moments (before and after
the treatment with oral anticoagulant) it can’tb es a i d
that the anticoagulation increased or decreased the QoL
perception of the patient, although the cross-section
study permits to describe the QoL perception of the stu-
died population. This study is an important contribution
to the understanding of this subject, since most of the
information available about the relationship between
QoL and anticoagulation comes from researches that
have been conducted in other countries, whose
Table 4 Factors that influence the perception of QoL
Factors that influence positively the perception of QoL Factors that influence negatively the perception of QoL
Low education level (DASS) Previous hemorrhagic event
Treatment length superior to 1 year Presence of comorbidities 20,8
Drug interactions
Low education level (SF36)
Younger age group
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tural and socio economic differences and by the way the
health system is organized.
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